logo-loader
viewGW Pharmaceuticals plc

GW Pharmaceuticals seizure drug aces phase three trial

GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.

A dying child
Lennox-Gastaut syndrome is a severe form of childhood epilepsy

GW Pharmaceuticals plc (NASDAQ:GWPH, LON:GWP) cannabinoid drug Epidiolex has achieved primary endpoint in treating Lennox-Gastaut syndrome - a severe form of childhood epilepsy - speeding through phase three trials.

Back in June, the group’s first pivotal phase three study of Epidiolex for the treatment of seizures in connection with the syndrome revealed favourable results. And then in March, the group released positive results in connection with Dravet syndrome.

Epidiolex was well tolerated during the trial period. The adverse pattern of events was in line with the previously reported two Phase 3 studies.

GW Pharmaceuticals expects to file a new drug application to the FDA in the first half of next year.

 "We feel a tremendous sense of urgency to stop seizures, and believe that the pursuit of new therapies offers hope to individuals who have no currently available therapy to effectively stop their seizures,” said chief executive Philip Gattone.

Shares trading on the London Stock Exchange rose 11% to 775.5p. 

Quick facts: GW Pharmaceuticals plc

Price: - -

NASDAQ:GWP
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Thunderbird Entertainment sees strong third quarter results...

Thunderbird Entertainment (CVE: TBRD-OTC: THBRF) CEO Jennifer Twiner McCarron joined Steve Darling from Proactive Vancouver to share news the company has released their 3rd quarter financial numbers which saw a 40 per cent increase from Q-3 of last year. Twiner-McCarron talks about what led...

1 day, 2 hours ago

2 min read